https://www.sciedupress.com/journal/index.php/crim/issue/feedCase Reports in Internal Medicine2022-05-26T06:40:32-07:00Isabel Graycrim@sciedupress.comOpen Journal Systems<p><img style="float: right; padding-left: 20px; padding-right: 20px;" src="/journal/public/site/images/crim/crim.jpg" alt="" width="300" /><em>Case Reports in Internal Medicine (CRIM)</em> is a peer-reviewed international journal dedicated to promoting scholarly exchange among teachers and researchers in the field of internal medicine. The journal is published quarterly in both print and online versions by the Sciedu Press. The online version could be browsed and downloaded free of charge.</p><p>Authors are encouraged to submit complete, unpublished, original, and full-length articles that are not under review in any other journals. The journal is striving to achieve high quality through double-blind peer review, as specified in <a href="http://web.sciedu.ca/author-guide.html">Author Guidelines</a>.</p><p><strong>CRIM is included in</strong>:</p><ul><li><a style="font-size: 10px;" href="https://scholar.google.com/citations?user=iK2LdUkAAAAJ&hl=en">Google Scholar</a></li><li><span style="font-size: 10px;"><span style="font-size: 10px;">SHERPA/RoMEO</span></span></li></ul><p>To facilitate rapid publication and to minimize administrative costs, the journal accepts <a href="/journal/index.php/crim/about/submissions#onlineSubmissions">Online submission</a> and <a href="mailto:crim@sciedupress.com">Email submission</a>. All manuscripts and any supplementary material can be submitted via the journal’s Online Submission and peer-review system or email to <a href="mailto:crim@sciedupress.com">crim@sciedupress.com</a>. For online submission, please create a new account and then follow the instructions given on the screen.</p><p><strong>CRIM’s Sections</strong></p><p><strong></strong>Case Reports, Case Studies, Reviews.</p>https://www.sciedupress.com/journal/index.php/crim/article/view/21217Ballismus Secondary to Antihistamine Use2022-05-26T06:38:20-07:00Michael James Brockmanmbrockman1@gmail.comAnne Taylorannietaylor182@gmail.comFarida EidFaridaEid@gmail.comSuranjana Dey; MDsdey4370@gmail.comShawn Corcoran; MDshawncorcoran@gmail.com<span id="docs-internal-guid-36d4d1a2-7fff-c70b-3c96-b31ad235af37" style="font-size: 11pt; font-family: Arial; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;">Antihistamine usage is commonplace for alleviating allergy symptoms, though they are not without side-effects. We present a case of antihistamine use precipitating upper and lower extremity ballismus in a patient. We also discuss other case reports which outline similar dopaminergic dysregulation secondary to antihistamine usage, as well as our recommendations for prevention of these symptoms.</span>2022-03-25T07:00:28-07:00Copyright (c) 2022 Case Reports in Internal Medicinehttps://www.sciedupress.com/journal/index.php/crim/article/view/20985Activating Dormant Strongyloidiasis Secondary to COVID-19 Treatment2022-05-26T06:40:32-07:00Fahad A AlKaabbaFahadAlQabba@gmail.comHolman LiFahadAlQabba@gmail.comFarrah IbrahimFahadAlQabba@gmail.com<p>The SARS-CoV-2 pandemic has grown into a major global concern with huge efforts to combat the spread. Exaggerated inflammatory response plays a major role in which was the rationale to use corticosteroids as a treatment option. However, multiple studies showed an association between of opportunistic and bacterial infections in patients under corticosteroid therapy. We report a case of a 76-year old patient diagnosed with COVID-19 pneumonia, treated with 10 days Dexamethasone and Remdesivir who presented with abdominal symptoms with eosinophilia. Biopsy and stool studies revealed strongyloides stercoralis larvae. The patient was treated with 2 doses of Ivermectin with significant clinical resolution. Clinician should have high clinical suspicion for Strongloydiasis in patients who have lived or visited <em>Strongyloides stercoralis</em> endemic areas and for patients with unexplained eosinophilia. Prompt treatment with Ivermectin is crucial for confirmed cases and should be also implemented empirical in high risk groups, where obtaining a diagnosis is unfeasible.</p>2022-05-26T06:38:10-07:00Copyright (c) 2022 Case Reports in Internal Medicine